Braftovi Mektovi offers promise for unresectable or metastatic melanoma

By Brian Buntz | July 21, 2021

braftovi mektovi Array BioPharma Pfizer Braftovi Mektovi from Array BioPharma won FDA approval in 2018 for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

Pfizer acquired Array BioPharma in 2019.

Braftovi Mektovi is an example of a BRAF/MEK inhibitor combination. The BRAF gene supports chemical signaling between the cell’s nuclear and the cell’s exterior. The MEK gene, conversely, guides the process of synthesizing MEK1 protein kinase.

Other examples of BRAF/MEK include Tafinlar (dabrafenib) and Mekinist (trametinib) from Novartis, and Zelboraf (vemurafenib) and Cotellic (cobimetinib) from Plexxikon and Genentech.

Filed Under: Oncology
Tagged With: Array BioPharma, Braftovi, Mektovi, melanoma, Pfizer

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.